MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome
Open Access
- 13 November 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 122 (6), 1391-1399
- https://doi.org/10.1002/ijc.23219
Abstract
The DNA repair protein O6‐methylguanine‐DNA methyltransferase (MGMT) plays a pivotal role in alkylating drug resistance. Here, we determined MGMT activity in primary and recurrent glioblastomas (GBM, WHO grade IV) of patients who received radiation therapy (RT) or RT plus chemotherapy with alkylating agents (temozolomide, chloroethylnitrosoureas). The mean MGMT activity of untreated GBM was 37 ± 45 (range 0–205) fmol/mg proteins. In the 1st, 2nd and 3rd recurrences, MGMT activity increased from 66 ± 50 (13–194) to 68 ± 44 (14–143) and 182 ± 163 (64–423) fmol/mg protein, respectively. Comparing patients who received RT only with RT plus chemotherapy, a significant increase of MGMT in 1st recurrences was only found after treatment with RT plus chemotherapy, indicating either selection of MGMT expressing cells or induction of the MGMT gene by alkylating agents. The p53 status was not significantly related to the MGMT expression level, although a trend for lower MGMT activity in p53 positively stained tumors was observed. Patients expressing MGMT activity of ≤30 fmol/mg protein in the pretreatment tumor had a significant better therapeutic response than patients expressing MGMT above this level, which was shown by Kaplan‐Meyer curves and the recurrence free interval after primary tumor resection. In patients who received RT only, this correlation was not found. The data revealed a threshold of MGMT expression (30 fmol/mg protein) below which patients respond better to alkylating agents. Therefore, determination of MGMT activity in the primary tumor appears to be useful in predicting the outcome of GBM therapy.Keywords
Funding Information
- DFG (KA 724/13-1, 13/2, SFB432/B7)
This publication has 45 references indexed in Scilit:
- Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide TreatmentClinical Cancer Research, 2007
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- O6-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 CohortJournal of Clinical Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Induction of the DNA repair gene O6-methylguanine—DNA methyltransferase by dexamethasone in glioblastomasJournal of Neurosurgery, 2004
- O6‐alkylguanine‐DNA alkyltransferase: Role in carcinogenesis and chemotherapyBioEssays, 2002
- Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugsInternational Journal of Cancer, 1996
- Constitutive expression and inducibility of O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in rat liver cells exhibiting different status of differentiationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1995
- Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agentsMutation Research - Reviews in Mutation Research, 1990
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976